PUK11 A COST-UTILITY ANALYSIS OF SOLIFENACIN 5 MG AND SOLIFENACIN 10 MGVERSUS TOLTERODINE ER 4 MG IN THE PHARMACOLOGICAL TREATMENT OF PATIENTS WITH OVERACTIVE BLADDER (OAB)

Nov 1, 2008, 00:00
10.1016/S1098-3015(10)67125-2
https://www.valueinhealthjournal.com/article/S1098-3015(10)67125-2/fulltext
Title : PUK11 A COST-UTILITY ANALYSIS OF SOLIFENACIN 5 MG AND SOLIFENACIN 10 MGVERSUS TOLTERODINE ER 4 MG IN THE PHARMACOLOGICAL TREATMENT OF PATIENTS WITH OVERACTIVE BLADDER (OAB)
Citation : https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(10)67125-2&doi=10.1016/S1098-3015(10)67125-2
First page :
Section Title :
Open access? : No
Section Order : 960
Categories :
Tags :
Regions :
ViH Article Tags :